[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:hyperuricemia":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":42,"states":43},"Hyperuricemia",5,[7,15,22,29,35],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07089875","A Study of Dotinurad Versus Allopurinol in Participants With Gout",[11],"Phase 3","RECRUITING","2026-08-26T02:19:11.399072Z","2026-07-05T05:32:16.731455Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT06674109","SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial",[19],"Phase 4","2026-08-26T02:18:17.007929Z","2026-06-05T00:55:50.372751Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":27,"content_modified":28},"NCT06859073","A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia",[26],"Phase 1","2026-08-26T02:17:56.243868Z","2026-05-05T02:43:29.691634Z",{"nct_id":30,"title":31,"phases":32,"status":12,"updated_at":33,"content_modified":34},"NCT07089888","A Study of Dotinurad Versus Allopurinol in Tophaceous Gout",[11],"2026-08-26T02:18:24.494016Z","2026-05-05T02:43:29.040134Z",{"nct_id":36,"title":37,"phases":38,"status":12,"updated_at":40,"content_modified":41},"NCT03899883","Uric Acid Lowering Trial in Youth Onset T2D",[39],"Phase 2","2026-08-03T00:53:18.104133Z","2026-07-05T03:45:20.245482Z",[],[44,48,51,54],{"state":45,"count":46,"slug":47},"California",3,"california",{"state":49,"count":46,"slug":50},"Colorado","colorado",{"state":52,"count":46,"slug":53},"Maryland","maryland",{"state":55,"count":46,"slug":56},"Massachusetts","massachusetts"]